PDS Biotech to Participate at Upcoming Investor Conferences
May 17 2022 - 8:00AM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing a growing pipeline of molecularly
targeted cancer immunotherapies and infectious disease vaccines
based on the Company’s proprietary Versamune® and Infectimune™
T-cell activating technologies, today announced that its management
will present at the H.C. Wainwright Global Investment Conference
and the LD Micro Invitational and will participate at the UBS
Healthcare Virtual One-on-One Day.
H.C. Wainwright Global Investment
ConferenceDate: Tuesday, May 24, 2022Time: 7:00 AM
EDTInvestors can register for the conference here
UBS Healthcare Virtual One-on-One DayDate:
Wednesday, June 1, 2022
LD Micro Invitational ConferenceDate:
Wednesday, June 8, 2022Time: 7:30 AM PDTVirtual Viewers:
LivestreamFollowing the conferences, a webcast replay of the
presentations will be available on the Investor section of the
company’s website, PDS Biotechnology. About PDS
BiotechnologyPDS Biotech is a clinical-stage immunotherapy
company developing a growing pipeline of molecularly targeted
cancer and infectious disease immunotherapies based on the
Company’s proprietary Versamune® and Infectimune™ T-cell
activating technology platforms. Our Versamune®-based products have
demonstrated the potential to overcome the limitations of current
immunotherapy by inducing in vivo, large quantities of
high-quality, highly potent polyfunctional tumor specific CD4+
helper and CD8+ killer T-cells. PDS Biotech has developed multiple
therapies, based on combinations of Versamune® and
disease-specific antigens, designed to train the immune system to
better recognize diseased cells and effectively attack and destroy
them. The Company’s pipeline products address various cancers
including HPV16-associated cancers (anal, cervical, head and neck,
penile, vaginal, vulvar) and breast, colon, lung, prostate and
ovarian cancers.
Our Infectimune™ -based vaccines have demonstrated the potential
to induce not only robust and durable neutralizing antibody
responses, but also powerful T-cell responses including
long-lasting memory T-cell responses. To learn more, please
visit www.pdsbiotech.com or follow us on Twitter at
@PDSBiotech.
Investor Contact:Rich CockrellCG CapitalPhone:
+1 (404) 736-3838pdsb@cg.capital
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Aug 2024 to Sep 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Sep 2023 to Sep 2024